1. Development of a Center for Personalized Cancer Care at a Regional Cancer Center 
Brian R. Lane, Jeffrey Bissonnette, Tracy Waldherr, Deborah Ritz-Holland, Dave Chesla, Sandra L. Cottingham, Sheryl Alberta, Cong Liu, Amanda B. Thompson, Carrie Graveel, Jeffrey P. MacKeigan, Sabrina L. Noyes, Judy Smith, Nehal Lakhani, Matthew R. Steensma Mark Enter, Kimberly Mohr, Samer Al-Homsi, Stephanie Williams, Marlee Bogema, Kirk Gates, Marianne Melnik, Mathew Chung, Thomas Southwell, Anne Wilds, Kimberly Collison, Timothy O'Rourke, Amy VanderWoude, Alan Campbell, Mark Campbell, Brett Brinker, Julian Schink, Leigh Seamon, Mary Winn Brian R. Lane, Jeffrey Bissonnette, Tracy Waldherr, Deborah Ritz-Holland, Dave Chesla, Sandra L. Cottingham, Sheryl Alberta, Cong Liu, Amanda B. Thompson, Carrie Graveel, Jeffrey P. MacKeigan, Sabrina L. Noyes, Judy Smith, Nehal Lakhani, Matthew R. Steensma Mark Enter, Kimberly Mohr, Samer Al-Homsi, Stephanie Williams, Marlee Bogema, Kirk Gates, Marianne Melnik, Mathew Chung, Thomas Southwell, Anne Wilds, Kimberly Collison, Timothy O'Rourke, Amy VanderWoude, Alan Campbell, Mark Campbell, Brett Brinker, Julian Schink, Leigh Seamon, Mary Winn 
The Journal of Molecular Diagnostics 
Volume 17, Issue 6, Pages (November 2015)
DOI: /j.jmoldx
Copyright © 2015 American Society for Investigative Pathology and the Association for Molecular Pathology Terms and Conditions

2. Figure 1
Clinical trial CONSORT diagram. Flow diagram of the phases of our pilot trial, which included 15 patients. Two patients were allocated according to biopsy samples, whereas 13 were allocated according to surgical samples. These samples underwent molecular analysis and next-generation sequencing to generate a profiling report that indicated the mutations found. The result reveal the effect on treatment decision (11 of 15 patients had potentially actionable mutations).
The Journal of Molecular Diagnostics  , DOI: ( /j.jmoldx )
Copyright © 2015 American Society for Investigative Pathology and the Association for Molecular Pathology Terms and Conditions

3. Figure 2
Diagram outlining workflow and composition of the tumor sequencing advisory board (TSAB). Patients are scheduled for surgery or biopsy and asked to consent to have their specimens used for research purposes through the biorepository. The pathology department processes the tissue and extracts DNA. A pathologists reviews the specimen. The samples are then sent to the Advanced Technology Laboratory for next-generation sequencing and Sanger sequencing for validation. The genetic counselor analyzes the results and generates a report that identifies actionable mutations. This report also outlines available clinical trials based on the identified mutations. The results are then provided to the clinician to review and assess treatment. Simultaneously, the TSAB reviews and discusses this report among the group. The TSAB formulates its recommendations and provides this to the clinician. The clinician formulates the data received and relays the best treatment regimen to the patient. IRB, institutional review board.
The Journal of Molecular Diagnostics  , DOI: ( /j.jmoldx )
Copyright © 2015 American Society for Investigative Pathology and the Association for Molecular Pathology Terms and Conditions

4. Figure 3
Mutations detected in the metastatic tissue samples from patient 10a. The patient presented with primary adenocarcinoma in the sigmoid colon. After surgical excision (stage IIB T4N0M0), the patient received FOLFOX adjuvant chemotherapy. The patient developed metastatic disease 4 years later, which was treated by excision of all gross disease and hyperthermic intraperitoneal chemotherapy with mitomycin C. The patient received no further treatment until metastasis was identified 1 year later. Metastatic evaluation revealed multiple abdominal tumors that were amenable to resection. The patient underwent complete debulking and hyperthermic intraperitoneal chemotherapy with oxaliplatin. Cancer HotSpot Panel version 2 was performed on five tissue metastatic samples with mutations identified as indicated below. Tumors with BRAF, PTEN, TP53, and SMAD4 mutations are indicated, whereas no mutations were identified in the secondary colorectal tumor.
The Journal of Molecular Diagnostics  , DOI: ( /j.jmoldx )
Copyright © 2015 American Society for Investigative Pathology and the Association for Molecular Pathology Terms and Conditions